Advertisement
Screener

ENTRADA THERAPEUTICS, INC. (TRDA) Accounts Payable

2.8 / 5 stars · 68/120 Roast Me

ENTRADA THERAPEUTICS, INC. Accounts Payable

ENTRADA THERAPEUTICS, INC. (TRDA) had Accounts Payable of $3.75 million as of 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current

us-gaap:AccountsPayableCurrent · last filed 2026-08-05

  • 2026-06-30: Accounts Payable, Current $3.75M.
  • 2026-03-31: Accounts Payable, Current $2.93M.
  • 2025-12-31: Accounts Payable, Current $2.29M.
  • 2025-09-30: Accounts Payable, Current $3.17M.
Period endAccounts Payable, Current
2026-06-30$3.75M
10-Q · filed 2026-08-05
2026-03-31$2.93M
10-Q · filed 2026-05-07
2025-12-31$2.29M
10-Q · filed 2026-08-05
2025-09-30$3.17M
10-Q · filed 2025-11-06
2025-06-30$1.86M
10-Q · filed 2025-08-06
2025-03-31$2.19M
10-Q · filed 2025-05-08
2024-12-31$4.26M
10-K · filed 2026-02-26
2024-09-30$1.29M
10-Q · filed 2024-11-05
2024-06-30$1.64M
10-Q · filed 2024-08-13
2024-03-31$2.53M
10-Q · filed 2024-05-07
2023-12-31$3.28M
10-K · filed 2025-02-27
2023-09-30$752.00K
10-Q · filed 2023-11-07
2023-06-30$2.42M
10-Q · filed 2023-08-08
2023-03-31$6.47M
10-Q · filed 2023-05-10
2022-12-31$5.99M
10-K · filed 2024-03-13
2022-09-30$1.34M
10-Q · filed 2022-11-07
2022-06-30$4.62M
10-Q · filed 2022-08-11
2022-03-31$2.93M
10-Q · filed 2022-05-12
2021-12-31$706.00K
10-K · filed 2023-03-06
2021-09-30$2.28M
10-Q · filed 2021-12-09
2020-12-31$1.60M
10-K · filed 2022-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55